The influence of chronic lymphocytic thyroiditis (CLT) on clinicopathological features and behavior of differentiated thyroid carcinoma (DTC) is still debated. In the present study, we aimed to evaluate the prognosis of DTC on the presence of CLT. A total of 649 total thyroidectomized patients (379 female, 270 male) with DTC, who had follow-up data for at least 36 months were included. Clinical, histopathological data, preoperative thyroid peroxidase antibody (TPO-ab), thyroglobulin antibody (Tg-ab), thyroid-stimulating hormone (TSH) levels, and presence of recurrent/persistent disease (R/PD) were evaluated retrospectively. Presence of CLT was defined by histopathology. Frequency of CLT was 32% (n = 208) among DTC patients. Mean tumor size (maximal diameter) was smaller in CLT group when compared to non-CLTs (p = 0.006). Capsular invasion, vascular invasion, tumor stage, risk groups, and R/PD were negatively associated with CLT (p < 0.01, p = 0.04, p = 0.03, p = 0.02, p < 0.01, respectively). Extrathyroidal extension was more frequent in non-CLT group when compared CLT (p = 0.052). Preoperative TSH level was positively associated with lymph node metastasis (LNM) and higher in patients with lateral LNM when compared to central LNM (p < 0.01). Central LNM, lateral LNM, stage 4 tumor, and intermediate- and high-risk tumor groups increased the risk of R/PH, 2.5-, 2.9-, 12.7-, 2.3-, and 4.2-fold, respectively. Presence of CLT was independently related with favorable outcomes, as the risk of R/PD was decreased by 0.49-fold. In conclusion, coexistence of CLT was negatively associated with tumor size, capsular invasion, vascular invasion, and tumor stage in DTC. Risk of R/PD was decreased by approximately half in patients with CLT.

慢性淋巴细胞性甲状腺炎（CLT）对分化型甲状腺癌（DTC）临床病理特征和行为的影响仍存在争议。在本研究中，我们旨在评估 DTC 对 CLT 存在的预后。共纳入 649 名甲状腺切除患者（379 名女性，270 名男性）并具有至少 36 个月的随访数据的 DTC。回顾性评估临床、组织病理学数据、术前甲状腺过氧化物酶抗体 (TPO-ab)、甲状腺球蛋白抗体 (Tg-ab)、促甲状腺激素 (TSH) 水平和复发/持续性疾病 (R/PD) 的存在。CLT 的存在由组织病理学定义。 DTC 患者的 CLT 频率为 32% ( n = 208)。与非 CLT 相比，CLT 组的平均肿瘤大小（最大直径）更小（p  = 0.006）。包膜浸润、血管浸润、肿瘤分期、风险组和 R/PD 与 CLT 呈负相关（分别为p  < 0.01、p  = 0.04、p  = 0.03、p  = 0.02、p  < 0.01）。与 CLT 相比，非 CLT 组的甲状腺外扩展更频繁（p  = 0.052）。术前 TSH 水平与淋巴结转移 (LNM) 呈正相关，与中央 LNM 相比，外侧 LNM 患者的 TSH 水平更高（p < 0.01)。中央 LNM、外侧 LNM、4 期肿瘤和中高危肿瘤组分别使 R/PH 风险增加了 2.5、2.9、12.7、2.3 和 4.2 倍。CLT 的存在与有利的结果独立相关，因为 R/PD 的风险降低了 0.49 倍。总之，CLT 的共存与 DTC 中的肿瘤大小、包膜浸润、血管浸润和肿瘤分期呈负相关。CLT 患者的 R/PD 风险降低了大约一半。